Abstract:Imbalance miRNAs contribute to tumor formation; therefore, the development of small-molecule compounds that regulate miRNA biogenesis is an important strategy in oncotherapy. Here, (−)-Gomisin M1 (GM) was found to modulate miRNA biogenesis to inhibit the proliferation, migration, and invasion of hepatocellular carcinoma (HCC) cells. GM modulated expression profiles of miRNA and protein in HCC cells and suppressed tumor growth in a mouse model. Mechanistically, GM affected miRNA maturation by targeting TAR RNA-binding protein 2 (TRBP), with an efficacy higher than that of enoxacin, and promoted the binding of TRBP with Dicer. Structural simplification and a preliminary structure–activity relationship study via the synthesis of 20 GM derivatives showed that compound 9 exhibited more potent inhibitory activity in HCC cell proliferation and affinity for TRBP than did GM. These results suggest that TRBP may be a novel potential therapeutic target in HCC and compound 9 may be a potential drug candidate for the treatment of HCC.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00018?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00018</a>.Additional figures illustrating the screening (Figure S1), the activities of GM (Figures S2–S5), miRNAomics and proteomics analysis (Figures S7–S14), the effect of GM on the expression of RISC elements (Figure S15), evidence that GM did not target Dicer or AGO2 (Figure S16), TRBP expression after transfection (Figure S17), activities of compounds 3, 7, 9, and 10 in HeLa-miR-21-luciferase cells (Figure S18), the KD values of compounds 3, 7, 9, and 10 (Figure S19), the activity of GM analogues against SK-Hep-1 cells (Figure S20), a comparison of the activity of GM and compound 9 (Figure S21), and the effect of compound 21 in HeLa-miR-21-luciferase cells (Figure S22), evidence that compound 21 did not target PIWIL3 or TPO2β, miRNAomics and proteomics data (Tables S1–S3), sequences of primers (Tables S4 and S5), NMR spectra, and HPLC data of (−)-Gomisin M1 and 7 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00018/suppl_file/jm1c00018_si_001.pdf">PDF</a>)Molecular formula strings of GM and 1–21 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00018/suppl_file/jm1c00018_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction Against Hepatocellular Carcinoma Via the Modulation of Microrna Biogenesis.

Research Progress of MicoRNA in Molecular Targeting Treatment of Hepatocellular Carcinoma

Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma

Implication of Myeloid Differentiation Factor 88 Inhibitor TJ-M2010-5 for Therapeutic Intervention of Hepatocellular Carcinoma.

Microrna-134 Inhibits Hcc Cell Growth And Migration Through The Akt/Gsk3 Beta/Snail Signaling Pathway

Cross-regulation Between Micrornas and Key Proteins of Signaling Pathways in Hepatocellular Carcinoma

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Tumor-triggered Personalized Microrna Cocktail Therapy for Hepatocellular Carcinoma

A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter

Identification of novel inhibitors of the transcriptional coactivator MRTF-A for HCC therapy

Therapeutics Based on microRNA: A New Approach for Liver Cancer

Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma

Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy

Identification and validation of key miRNAs and a microRNA-mRNA regulatory network associated with liver cancer

MiR-4310 regulates hepatocellular carcinoma growth and metastasis through lipid synthesis

Abstract 1645: DNA-damaging Compound 0404 Effectively Inhibits Hepatocellular Carcinoma by Upregulation of Mir-34A and Mir-200C Expression

microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA

Tumor-triggered MicroRNA Cocktail Therapy for Hepatocellular Carcinoma

Targeting miRNA for Colorectal Cancer: In Silico Identification and Physics-based De Novo Modeling of Oncogenic miR-135b for Small Molecule RNA Therapy

Identification of Mir-101-3p Targets and Functional Features Based on Bioinformatics, Meta-Analysis and Experimental Verification in Hepatocellular Carcinoma.

MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1